Journal Der Deutschen Dermatologischen Gesellschaft最新文献_第9页

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities. 西米单抗治疗皮肤鳞状细胞癌：一项着眼于晚期毒性的长期随访研究。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-02 DOI: 10.1111/ddg.70440

Marco Rubatto, Alice Baggi, Roberta Depenni, Michele Guida, Paolo Antonio Ascierto, Paola Queirolo, Ketty Peris, Francesco Spagnolo, Luca Bianchi, Federica De Galitiis, Manuel Zamparini, Ilaria Proietti, Riccardo Marconcini, Andrea Botticelli, Vito Barbieri, Salvatore Alfieri, Maria Concetta Fargnoli, Marcella Occelli, Paolo Fava, Alessio Capacchione, Valentina Comunanza, Paolo Bossi, Pietro Quaglino

{"title":"Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.","authors":"Marco Rubatto, Alice Baggi, Roberta Depenni, Michele Guida, Paolo Antonio Ascierto, Paola Queirolo, Ketty Peris, Francesco Spagnolo, Luca Bianchi, Federica De Galitiis, Manuel Zamparini, Ilaria Proietti, Riccardo Marconcini, Andrea Botticelli, Vito Barbieri, Salvatore Alfieri, Maria Concetta Fargnoli, Marcella Occelli, Paolo Fava, Alessio Capacchione, Valentina Comunanza, Paolo Bossi, Pietro Quaglino","doi":"10.1111/ddg.70440","DOIUrl":"10.1111/ddg.70440","url":null,"abstract":"Background and objectives: Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC).Patients and methods: We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with emphasis on late-onset toxicities and long-term clinical outcomes. Late toxicities were defined as treatment-related adverse events (TRAEs) occurring ≥ 6 months after therapy initiation. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated.Results: Median PFS was 9 months. 58 (43.3%) patients experienced progression while 76 (56.7%) maintained a response. Median OS was 21 months (range 0-32), and 67 (50%) patients died. The ORR and DCR were 58.9% and 72.4%, respectively. CR increased from 15% (20 patients) in September 2020 to 19.4% (26 patients) in early 2022. 15 (11.2%) patients had at least one TRAE and 2 of them stopped cemiplimab. Median time to TRAE onset was 12 months (range 6-23); all events resolved after therapy discontinuation, and none of the AEs became chronic.Conclusions: With a longer follow-up than that reported in registrational studies and real-world reports, the clinical activity of cemiplimab was confirmed, with a limited incidence of late toxicities. However, some TRAEs may emerge after prolonged treatment.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ropeginterferon-α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients. ropeg干扰素-α2b治疗蕈样真菌病和ssamzary综合征41例的安全性和有效性

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-02 DOI: 10.1111/ddg.70546

Stefanie Porkert, Juliette M Kersten, Rosanne Ottevanger, Hanna Schratter, Regina Fink-Puches, Van Anh Nguyen, Farzaneh Sadeghyar, Johanna Latzka, Franz Trautinger, Magdalena Hoellwerth, Peter Koelblinger, Nicole Pfannschmidt, Nina Haering, Johannes Griss, Maarten H Vermeer, Constanze Jonak

{"title":"Ropeginterferon-α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients.","authors":"Stefanie Porkert, Juliette M Kersten, Rosanne Ottevanger, Hanna Schratter, Regina Fink-Puches, Van Anh Nguyen, Farzaneh Sadeghyar, Johanna Latzka, Franz Trautinger, Magdalena Hoellwerth, Peter Koelblinger, Nicole Pfannschmidt, Nina Haering, Johannes Griss, Maarten H Vermeer, Constanze Jonak","doi":"10.1111/ddg.70546","DOIUrl":"10.1111/ddg.70546","url":null,"abstract":"Background and objectives: Pegylated interferon-α2a became the off-label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non-pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon-α2b in MF/SS.Patients and methods: We performed a retrospective multicenter analysis at 5 Austrian centers and 1 Dutch center, including 41 patients with MF or SS who were treated with ropeginterferon-α2b between October 2024 and September 2025.Results: We included 38 MF (early-stage n = 16, advanced-stage n = 22) and 3 SS patients. In 70.7 % of cases (29/41), ropeginterferon-α2b was administered as part of a combination treatment with a mean dose of 100 µg every 2 weeks. We observed an overall response rate of 48.8 % over a median treatment duration of 6 months (range 1-11 months). Treatment was discontinued in 16 patients (39.0 %) after a median of 4 months because of progressive disease (n = 9), adverse events (n = 4), or other reasons (n = 3). Most frequent AEs were fatigue/flu-like symptoms (32.5 %), anemia (15 %), neutropenia (15 %), lymphopenia (10 %), and elevated liver enzymes (10 %), classified as grade 1 or 2.Conclusions: Conclusions: This study provides initial evidence that ropeginterferon-α2b may be effective and well tolerated in patients with CTCL. Although interpretation is limited by the small retrospective cohort and short follow-up, the observed outcomes appear comparable to those previously reported for other interferon-α formulations.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation loss. 伊马替尼对KIT突变后粘膜黑色素瘤的特殊治疗效果

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2025-10-25 DOI: 10.1111/ddg.15867

Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone

引用次数: 0

Multibacillary leprosy - a diagnostic and therapeutic challenge. 多菌性麻风病——诊断和治疗的挑战。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2026-02-16 DOI: 10.1111/ddg.70104x

Vera Baur, Christoph Lange, Axel Hueber, Walter Geißdörfer, Stefan Schmiedel, Andrea Vanegas Ramirez, Erwin Schultz, Felix Aurnhammer

引用次数: 0

Correlation of dermatoscopy and LC-OCT as a diagnostic extension for scabies. 皮镜检查与LC-OCT诊断疥疮的相关性。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2025-09-04 DOI: 10.1111/ddg.15945

Lukas Kofler, Uzay Cambaz, Maren Heinecke, Garance Hubert, Katrin Kofler

引用次数: 0

JAK inhibitors and menstrual cycle alterations: insights from a case series of 16 female patients. JAK抑制剂和月经周期改变：来自16名女性患者的病例系列的见解。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2026-03-12 DOI: 10.1111/ddg.70173

Luciano Ibba, Luigi Gargiulo, Matteo Bianco, Sara Di Giulio, Ruggero Cascio Ingurgio, Angela Alfano, Carlo A Vignoli, Mario Valenti, Paola Facheris, Chiara Perugini, Alessandra Narcisi, Antonio Costanzo

引用次数: 0

S1 guideline sweat gland carcinoma. S1指南汗腺癌。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2026-07-07 DOI: 10.1111/ddg.70107x

Mirjana Ziemer, Michael Erdmann, Abbas Agaimy, Jürgen C Becker, Almut Böer-Auer, Doris Helbig, Cornelia Erfurt-Berge, Alexander Frisman, Conrad Hempel, Ulrike Leiter, Friedegund Meier, Thomas Mentzel, Lara Racz, Silke Redler, Stefan Schliep, Clemens Seidel, Alpaslan Tasdogan, Jochen Utikal, Carsten Weishaupt, Selma Ugurel

{"title":"S1 guideline sweat gland carcinoma.","authors":"Mirjana Ziemer, Michael Erdmann, Abbas Agaimy, Jürgen C Becker, Almut Böer-Auer, Doris Helbig, Cornelia Erfurt-Berge, Alexander Frisman, Conrad Hempel, Ulrike Leiter, Friedegund Meier, Thomas Mentzel, Lara Racz, Silke Redler, Stefan Schliep, Clemens Seidel, Alpaslan Tasdogan, Jochen Utikal, Carsten Weishaupt, Selma Ugurel","doi":"10.1111/ddg.70107x","DOIUrl":"10.1111/ddg.70107x","url":null,"abstract":"The current classification of sweat gland carcinomas is based on histomorphological characteristics and distinguishes between more than 20 entities. Most patients are older, but some subtypes also affect middle-aged and younger patients. The majority of tumors arise de novo. Sweat gland carcinomas have nonspecific clinical features. The tumors are usually located in the head and neck area and on extremities, with the exception of extramammary Paget's carcinoma, which has an anogenital predilection. Sweat gland carcinomas occurring in the armpit may pose a histomorphological challenge in distinguishing them from metastatic or primary breast cancer. The diagnosis is made histopathologically via excisional biopsy. Histopathological subdifferentiation is essential for an accurate diagnosis. Metastasis initially occurs locally (per continuitatem), later to regional lymph nodes and distant organs. The treatment of choice is complete surgical excision with entire histopathological margin control (microscopically controlled surgery) or alternatively with wide local excision with a safety margin. Postoperative adjuvant radiotherapy is recommended for high-risk tumors. The data available for drug therapy of advanced tumors is generally weak, with the best results seen for chemotherapy using platinum derivatives. Furthermore, targeted therapies are possible, e.g., with HER2/neu or EGFR inhibitors, possibly in combination with chemotherapy. A risk-adapted regimen is recommended for the follow-up care.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":"e1356-e1385"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13551228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Annular lesions in distinct skin sites: mimickers in dermatopathology. 不同皮肤部位的环状病变：皮肤病理学的模拟者。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2026-03-25 DOI: 10.1111/ddg.70260

Bifica Sofia Lyngdoh, Mary Zothanpuii Chhangte, Pakesh Baishya, Neirita Hazarika

引用次数: 0

Early diagnosis of a case of lipoid proteinosis due to a previously undescribed deletion in ECM1 gene. 早期诊断一例脂质蛋白沉积症由于一个未描述的缺失在ECM1基因。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2025-10-22 DOI: 10.1111/ddg.15920

Miguel Mansilla-Polo, Daniel Martín-Torregrosa, Margarita Llavador-Ros, Francisco Martínez-Castellano, Montserrat Évole-Buselli

引用次数: 0

Chromoblastomycosis caused by Phialophora macrospora. 由大孢子紫孢菌引起的成色菌病。

IF 5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2026-09-01 Epub Date: 2026-02-28 DOI: 10.1111/ddg.70070

Ziwen Xu, Fangfang Bao, Changping Yu, Shufen Wang, Shengli Chen, Hong Liu, Mei Wu, Furen Zhang

引用次数: 0